Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -32.39%.

  • Biodesix's EBITDA Margin rose 1494.00% to -32.39% in Q3 2025 from the same period last year, while for Sep 2025 it was -40.61%, marking a year-over-year increase of 1235.00%. This contributed to the annual value of -48.37% for FY2024, which is 3585.00% up from last year.
  • As of Q3 2025, Biodesix's EBITDA Margin stood at -32.39%, which was up 33.28% from -48.55% recorded in Q2 2025.
  • Biodesix's 5-year EBITDA Margin high stood at -19.34% for Q1 2021, and its period low was -220.85% during Q1 2022.
  • Moreover, its 3-year median value for EBITDA Margin was -48.55% (2025), whereas its average is -64.08%.
  • In the last 5 years, Biodesix's EBITDA Margin spiked by 14,593bps in 2021 and then crashed by 20,150bps in 2022.
  • Over the past 5 years, Biodesix's EBITDA Margin (Quarterly) stood at -161.67% in 2021, then surged by 1,709bps to -144.58% in 2022, then spiked by 9,775bps to -46.84% in 2023, then skyrocketed by 1,429bps to -32.55% in 2024, then skyrocketed by 1,494bps to -32.39% in 2025.
  • Its EBITDA Margin was -32.39% in Q3 2025, compared to -48.55% in Q2 2025 and -50.87% in Q1 2025.